These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1428733)

  • 21. Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.
    Abromowitch M; Bowman WP; Ochs J; Rivera G
    J Clin Oncol; 1985 Jun; 3(6):789-92. PubMed ID: 3859585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma.
    Yau JC; Yap YY; Buzdar AU; Hortobagyi GN; Bodey GP; Blumenschein GR
    Cancer; 1985 Jan; 55(2):337-40. PubMed ID: 3880657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
    Bleyer WA; Sather HN; Nickerson HJ; Coccia PF; Finklestein JZ; Miller DR; Littman PS; Lukens JN; Siegel SE; Hammond GD
    J Clin Oncol; 1991 Jun; 9(6):1012-21. PubMed ID: 2033414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
    Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
    Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.
    Ichikawa M; Suzuki D; Inamoto J; Ohshima J; Cho Y; Saitoh S; Kaneda M; Iguchi A; Ariga T
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):239-41. PubMed ID: 22246157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
    Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
    J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
    Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A presumed transient hemolytic reaction following vinca alkaloids administration in patients with hematological malignancies].
    Iwata N; Wakamatsu E; Oike S; Umegae S; Omine M; Maekawa T; Tsuchiya J
    Rinsho Ketsueki; 1984 May; 25(5):649-54. PubMed ID: 6590896
    [No Abstract]   [Full Text] [Related]  

  • 29. Vindesine-prednisone in the treatment of blast crisis of chronic myeloid leukemia.
    Lemoine F; Najman A; Laporte JP; Gorin NC; Duhamel G
    Cancer Treat Rep; 1985 Feb; 69(2):203-4. PubMed ID: 3855698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.
    Chen S; Wu D; Sun A; Qiu H; Jin Z; Tang X; Miao M; Fu Z; Ma X; Han Y; Hu X
    Am J Hematol; 2007 Oct; 82(10):942. PubMed ID: 17617780
    [No Abstract]   [Full Text] [Related]  

  • 31. Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.
    Ettinger LJ; Brecher M; Coleman M; Smithson WA; Patterson R; Russell EC; Necheles T; Jones B; Ohnuma T
    Med Pediatr Oncol; 1982; 10(1):35-43. PubMed ID: 7038420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL
    J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Winick NJ; Smith SD; Shuster J; Lauer S; Wharam MD; Land V; Buchanan G; Rivera G
    J Clin Oncol; 1993 Feb; 11(2):271-8. PubMed ID: 8426204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study.
    Uderzo C; Rondelli R; Dini G; Dallorso S; Messina C; Miniero R; Locatelli F; De Manzini A; Pession A; Balduzzi A
    Br J Haematol; 1995 Apr; 89(4):790-7. PubMed ID: 7772514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study.
    Buchanan GR; Boyett JM; Pollock BH; Smith SD; Yanofsky RA; Ghim T; Wharam MD; Crist WM; Vietti TJ; Johnson W
    Cancer; 1991 Jul; 68(1):48-55. PubMed ID: 2049752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
    Feig SA; Krailo MD; Harris RE; Baum E; Holcenberg JS; Kaizer H; Steinherz L; Pendergrass TW; Saunders EF; Warkentin PL
    Med Pediatr Oncol; 1992; 20(2):124-9. PubMed ID: 1734217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
    Chen YC; Ho CL; Kao WY; Hwang JM; Sheu LF; Chao TY
    Ann Hematol; 2001 Nov; 80(11):647-52. PubMed ID: 11757723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.
    Krivit W; Anderson J; Chilcote R; Pyesmany A; Chard R; Hammond D
    Am J Pediatr Hematol Oncol; 1980; 2(3):217-21. PubMed ID: 7001942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.